Physician profile
Jonathan Charney
NPI 1568593457
$20,306.34
in general payments reported to CMS, 2019-2025
46 companies · $3,008 in 2025
The $3,008 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,211 · 2020: $2,009 · 2021: $2,663 · 2022: $3,311 · 2023: $2,965 · 2024: $2,140 · 2025: $3,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,936 · Consulting Fee: $150 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.84 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,936.45 |
| Consulting Fee | $150.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.84 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,905.27 | 2019-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $1,293.30 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| E.R. Squibb & Sons, L.L.C. | $1,021.41 | 2020-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $924.60 | 2019-2024 | Ultomiris |
| Lundbeck LLC | $894.09 | 2021-2025 | Vyepti |
| Amgen INC. | $892.28 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $829.94 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $825.06 | 2019-2022 | |
| Allergan, INC. | $818.64 | 2019-2020 | |
| Lilly USA, LLC | $765.63 | 2019-2025 | Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.39 | 2021-2025 | Jardiance |
| Ucb, INC. | $706.06 | 2019-2025 | Rystiggo |
| Pfizer INC. | $612.09 | 2023-2025 | |
| Kyowa Kirin, INC. | $537.10 | 2019-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $524.02 | 2019-2023 | Austedo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Charney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.